查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2030 年生物學名藥市場預測 - 按藥物類別、製造類型、技術、用途、最終用戶和地區進行的全球分析
市場調查報告書
商品編碼
1339987

2030 年生物學名藥市場預測 - 按藥物類別、製造類型、技術、用途、最終用戶和地區進行的全球分析

Biosimilars Market Forecasts to 2030 - Global Analysis By Drug Class, Manufacturing Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

據Stratistics MRC預測，2023年全球生物學名藥市場規模將達到239億美元，預計到2030年將達到1002億美元，預測期內年複合成長率為22.7%。

生物學名藥，也稱為後續生物製品，幾乎是原研藥的精確複製品，但由不同的公司生產。多種急性和慢性疾病和病症正在用生物學名藥進行治療。使用生物學名藥捕獲人腦的電活動。

根據國際癌症研究機構2020的數據，2020年全球新增白血病患者人數預計為474,519人。

市場動態：

促進因素

  • 強大的產品平臺。
  • 擁有強大生物學名藥產品線的製藥公司處於有利地位，可以滿足對具有成本效益的生物製劑替代品不斷成長的需求。我們多樣化且廣泛的產品線涵蓋各種治療領域和病理，從而提供更廣泛的治療選擇。隨著越來越多的生物製劑專利到期，強大的產品平臺提供了新的生物學名藥的穩定來源，從而增加了市場競爭和可用性。

抑制因素

  • 開發成本高。
  • 開發生物學名藥是一個複雜且資源集中的過程，需要廣泛的研究、臨床試驗和監管部門的批准。生物學名藥的開發需要廣泛的研究、臨床試驗和監管部門的批准，公司必須通過廣泛的測試證明生物學名藥與參考生物製劑具有可比性，這是不可能的。此外，生物學名藥的法規環境通常比學名藥有更嚴格的要求，這可能會進一步增加開發成本。這些高成本可能會阻止一些製藥公司進入生物學名藥市場，限制市場競爭，並延遲向患者提供更便宜的生物學名藥。

機會：

  • 對生物學名藥的需求不斷成長。
  • 生物學名藥是昂貴生物製劑的經濟高效替代品，具有相似的治療功效和品質。隨著醫療保健成本的不斷上升以及對負擔得起的治療選擇的需求，生物學名藥在醫療保健提供者和患者中越來越受歡迎。世界各地的政府和醫療保健系統都鼓勵使用生物學名藥來改善救生藥物的獲取並降低醫療保健成本。隨著越來越多的生物製劑專利到期，生物學名藥市場正在迅速擴大，擴大了患者獲得重要治療的機會，並使製藥公司有能力在這個快速成長和充滿活力的領域競爭。希望會有機會這樣做。

威脅：

  • 製造複雜性。
  • 與傳統的小分子藥物不同，生物類似藥是在活細胞中製造的複雜生物化合物，其製造過程複雜而精細。細胞株、發酵、精製和翻譯後變化只是必須仔細控制以確保品質、功效和安全性一致性的眾多變量中的幾個。任何製造偏差或差異都可能影響最終產品與參考生物製品的相似性並威脅患者安全。與生物學名藥相關的嚴格法規限制和高昂的研究成本帶來了額外的挑戰，阻礙了一些公司進入市場，並限制了對患者友好的生物學名藥替代品的供應。

COVID-19 的影響：

  • 由於許多國家實施了封鎖，預計 COVID-19 大流行將對生物學名藥市場的成長產生負面影響。 COVID-19 大流行使製藥行業無法專注於研發，尤其是生物學名藥的研發。疫情期間，整個醫療保健行業都專注於開發救生產品。此外，疫情導致產品核准和上市延遲，進一步限制了生物學名藥行業的成長。
  • 重組非糖基化蛋白片段預計在預測期內將是最大的
  • 重組非糖基化蛋白片段是一類重要的生物製劑，用於治療癌症、自身免疫性疾病和炎症性疾病等多種疾病，因此生物學名藥市場預計將出現良好成長。非糖基化蛋白質的生物學名藥開發是一個很有前途的機會，可以為昂貴的參考生物製劑提供具有成本效益的替代品。一旦非糖基化生物製劑的專利到期，生物學名藥製造商可以利用這個機會為患者提供更便宜的治療選擇。然而，製造複雜性以及展示與參考產品的可比性給開發和批准過程帶來了挑戰。
  • 癌症領域預計在預測期內復合年複合成長率最高
  • 腫瘤學預計在預測期內復合年複合成長率最快。隨著全球癌症罹患率的上升，生物製劑已成為癌症領域不可或缺的一部分，但其高昂的成本給許多患者帶來了挑戰。生物學名藥提供了一種有前途的解決方案，為癌症治療中使用的昂貴生物製劑提供了更實惠的替代品。隨著各種癌症生物製劑的專利到期，生物學名藥開發商正專注於開發等效製劑，擴大醫療保健提供者和患者的選擇範圍。

佔比最大的地區

預計北美生物學名藥市場在預測期內將繼續佔據大部分市場佔有率。這是由於人們越來越關注先進的醫療基礎設施和具有成本效益的治療方案。隨著一些生物製劑失去專利獨占權，該地區生物學名藥的批准和市場准入有所增加。美國生物製品價格競爭和創新法案（BPCIA）等法規框架為生物學名藥的開發和商業化鋪平了道路。此外，製藥公司和醫療保健提供者之間的合作正在進一步推動生物學名藥的採用。

複合年複合成長率最高的地區：

預計亞太地區在預測期內年複合成長率最高。慢性病的增加、醫療保健成本的上升以及專利到期的生物製劑正在推動對具有成本效益的治療方案的需求。印度、韓國和中國等政府正在積極推動生物學名藥的採用，以提高醫療保健的可及性和可負擔性。此外，支持性的法規環境和簡化的核准流程正在鼓勵國內外製藥公司投資生物學名藥開發。

免費客製化服務：

訂閱此報告的客戶將收到以下免費客製化選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（注：基於可行性檢查）
  • 競爭標杆管理
    • 根據產品系列、地域分佈和戰略聯盟對主要企業進行基準測試

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 資料挖掘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球生物學名藥市場：按藥物類別

  • 重組非糖基化蛋白
    • 重組人生長激素
    • 顆粒細胞增生因子
    • 胰島素
    • 干擾素
  • 重組糖基化蛋白
    • 促紅細胞生成素
    • 單克隆抗體
      • 英夫利昔單抗
      • 利妥昔單抗
      • 阿達木單抗
      • 曲妥珠單抗
      • Bevacizumab
      • 依那西普
    • 促卵泡素
  • 重組肽
    • 依那西普
    • 特立帕肽
    • 抗凝物
  • 其他藥物類別

第6章 全球生物學名藥市場：按製造類型

  • 自主生產
  • 契約起草（名詞

第7章 全球生物學名藥市場：按技術分類

  • 質譜
  • 色譜法
  • 單克隆抗體技術
  • 重組DNA技術
  • 核磁共振（NMR）技術
  • 電泳
  • 生物測定

第8章 全球生物學名藥市場：按用途

  • 血液學
    • 中性粒細胞減少症
    • 貧血
  • 腫瘤學
    • 肺癌
    • 腦腫瘤
    • 乳腺癌
    • 宮頸癌
    • 結直腸癌
    • 白血病
      • 非霍奇金淋巴瘤 (NHL)
      • 慢性淋巴性白血病（CLL）
  • 慢性病
  • 自身免疫性疾病
    • 關節炎
      • 類風濕性關節炎
      • 乾癬性關節炎
      • 幼年型關節炎
      • 僵直性脊椎炎
    • 炎症性腸病（IBD）
      • 潰瘍性大腸炎
      • 克隆氏症
    • 銀屑病
  • 血液疾病
  • 生長激素缺乏症
  • 糖尿病
  • 其他用途

第9章 全球生物學名藥市場：按最終用戶分類

  • 醫院藥房
  • 零售藥房
  • 網上藥房
  • 其他最終用戶

第10章 全球生物學名藥市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章進展

  • 契約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章公司簡介

  • Coherus Biosciences Inc.
  • Boehringer Ingelheim International GMBH
  • Eli Lilly and Company
  • Fresenius Kabi Ag
  • Samsung Bioepis Co. Ltd
  • Amgen Inc.
  • LG Life Sciences（LG Chem）
  • Celltrion Healthcare
  • Biocad
  • Dr. Reddy's Laboratories LTD.
  • Viatris Inc.
  • Intas Pharmaceutical Ltd
  • Biocon Limited
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc.
  • Stada Arzneimittel AG
  • Novartis AG
Product Code: SMRC23694

According to Stratistics MRC, the Global Biosimilars Market is accounted for $23.9 billion in 2023 and is expected to reach $100.2 billion by 2030 growing at a CAGR of 22.7% during the forecast period. Biosimilars, also known as follow-on biologics, are almost exact replicas of the original drugs but are created by a different company. A variety of acute and chronic illnesses and disorders are treated with biosimilars.

According to the International Agency for Research on Cancer 2020, the estimated number of new leukemia cases in 2020 was 474,519 globally.

Market Dynamics:

Driver:

  • Strong product pipeline.
  • Pharmaceutical companies with robust pipelines of biosimilar products are well-positioned to meet the increasing demand for cost-effective alternatives to biologic drugs. A diverse and expansive pipeline allows for a broader range of therapeutic options, covering various therapeutic areas and medical conditions. As more biologic drugs approach patent expiration, a well-developed product pipeline can lead to a steady stream of new biosimilar offerings, enhancing competition and availability in the market.

Restraint:

  • High developmental costs.
  • Developing a biosimilar is a complex and resource-intensive process that involves extensive research, clinical trials, and regulatory approvals. Companies must demonstrate the biosimilar's comparability to the reference biologic through extensive testing, which requires substantial financial investment. Additionally, navigating the regulatory landscape for biosimilars, which often involves more stringent requirements compared to generic drugs, can further escalate development costs. These high costs deter some pharmaceutical companies from entering the biosimilars market, leading to limited competition and potentially delaying the availability of more affordable biosimilar alternatives for patients.

Opportunity:

  • Increasing demand for biosimilars.
  • Biosimilars are cost-effective alternatives to expensive biologic drugs, offering similar therapeutic effects and quality. With rising healthcare costs and the need for affordable treatment options, biosimilars have gained traction among healthcare providers and patients. Governments and healthcare systems worldwide are encouraging the use of biosimilars to enhance accessibility to life-saving medications and reduce healthcare expenditure. As more biologic drugs approach patent expiration, the biosimilars market is expected to expand rapidly, providing patients with greater access to critical treatments and creating opportunities for pharmaceutical companies to compete in this growing and dynamic sector.

Threat:

  • Complexities in manufacturing.
  • Biosimilars are complex biologic compounds made in living cells as opposed to conventional small-molecule medications, making the production procedure for them complex and delicate. Cell lines, fermentation, purification, and post-translational changes are just a few of the many variables that need to be carefully controlled in order to guarantee consistency in quality, effectiveness, and safety. Any manufacturing deviation or inconsistency might affect the final product's resemblance to the reference biologic and potentially jeopardize patient safety. The strict regulatory restrictions and expensive research costs related to biosimilars provide additional difficulties, deterring some businesses from joining the market and limiting the supply of patient-friendly biosimilar substitutes.

COVID-19 Impact:

  • The COVID-19 outbreak is anticipated to have a negative impact on the growth of the biosimilars market, owing to the implementation of lockdowns in many countries. The COVID-19 pandemic made it impossible for the pharmaceutical sector to concentrate on R&D efforts, particularly the creation of biosimilars. During the epidemic, the whole healthcare sector has concentrated on developing life-saving products. Additionally, pandemic conditions cause delays in product approvals and releases, which further limit the growth of the biosimilars industry.
  • The recombinant non-glycosylated proteins segment is expected to be the largest during the forecast period
  • The recombinant non-glycosylated proteins segment is expected to have lucrative growth in the biosimilars market as they represent a crucial class of biologic drugs used to treat various diseases, including cancer, autoimmune disorders, and inflammatory conditions. Biosimilar development for non-glycosylated proteins presents a promising opportunity to offer cost-effective alternatives to expensive reference biologics. As patents for non-glycosylated biologics expire, biosimilar manufacturers can capitalize on this opportunity to provide more affordable treatment options for patients. However, the complexity of manufacturing and demonstrating comparability to the reference products pose challenges in the development and approval processes.
  • The oncology segment is expected to have the highest CAGR during the forecast period
  • The oncology segment is anticipated to witness the fastest CAGR growth during the forecast period. With the rising incidence of cancer worldwide, biologic drugs have become essential in the oncology field, but their high costs pose challenges for many patients. Biosimilars offer a promising solution by providing more affordable alternatives to expensive biologics used in cancer therapies. As patents for various oncology biologics expire, biosimilar developers have focused on developing comparable versions, expanding the options available to healthcare providers and patients.

Region with largest share:

During the forecast period, it is expected that the North American Biosimilars market will continue to hold a majority of the market share. Due to its advanced healthcare infrastructure and growing focus on cost-effective treatment options. With several biologic drugs losing patent exclusivity, the region has seen an increase in biosimilars approvals and market entry. Regulatory frameworks, such as the Biologics Price Competition and Innovation Act (BPCIA) in the United States, have paved the way for biosimilars development and commercialization. Moreover, collaborations between pharmaceutical companies and healthcare providers have further facilitated biosimilars adoption.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period. The increasing prevalence of chronic diseases, rising healthcare costs, and the expiration of biologic drug patents has fuelled the demand for cost-effective treatment options. Governments in countries like India, South Korea, and China are actively promoting the adoption of biosimilars to enhance healthcare accessibility and affordability. Additionally, a supportive regulatory environment and streamlined approval processes have encouraged both domestic and international pharmaceutical companies to invest in biosimilar development.

Key players in the market:

Some of the key players in Biosimilars market include: Coherus Biosciences Inc., Boehringer Ingelheim International GMBH, Eli Lilly and Company, Fresenius Kabi Ag, Samsung Bioepis Co. Ltd, Amgen Inc., LG Life Sciences (LG Chem), Celltrion Healthcare, Biocad, Dr. Reddy's Laboratories LTD., Viatris Inc., Intas Pharmaceutical Ltd, Biocon Limited, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Stada Arzneimittel AG and Novartis AG.

Key Developments:

  • In May 2023, Boehringer Ingelheim received U.S. FDA clearance for Cyltezo Pen, a novel autoinjector choice for Cyltezo (adalimumab-adbm), an FDA-approved interchangeable biosimilar to Humira.
  • In January 2023, Amgen Inc. launched AMJEVITA (adalimumab-atto), a biosimilar to Humira (adalimumab) in United States.
  • In October 2022, Biocon and Yoshindo Inc., entered into an agreement for commercializing Biocon's pipeline products ustekinumab and bDenosumab in Japan.

Drug Classes Covered:

  • Recombinant Non-Glycosylated Proteins
  • Recombinant Glycosylated Proteins
  • Recombinant Peptides
  • Other Drug Classes

Manufacturing Types Covered:

  • In-house Manufacturing
  • Contract Manufacturing

Technologies Covered:

  • Mass Spectroscopy
  • Chromatography
  • Monoclonal Antibody Technology
  • Recombinant DNA Technology
  • Nuclear Magnetic Resonance (NMR) Technology
  • Electrophoresis
  • Bioassay

Applications Covered:

  • Hematology
  • Oncology
  • Chronic Diseases
  • Autoimmune Disease
  • Blood Disorders
  • Growth Hormone Deficiency
  • Diabetes
  • Other Applications

End Users Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Biosimilars Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Recombinant Non-Glycosylated Proteins
    • 5.2.1 Recombinant Human Growth Hormone
    • 5.2.2 Granulocyte Colony-Stimulating Factor
    • 5.2.3 Insulin
    • 5.2.4 Interferons
  • 5.3 Recombinant Glycosylated Proteins
    • 5.3.1 Erythropoietin
    • 5.3.2 Monoclonal Antibodies
      • 5.3.2.1 Infliximab
      • 5.3.2.2 Rituximab
      • 5.3.2.3 Adalimumab
      • 5.3.2.4 Trastuzumab
      • 5.3.2.5 Bevacizumab
      • 5.3.2.6 Etanercept
    • 5.3.3 Follitropin
  • 5.4 Recombinant Peptides
    • 5.4.1 Etanercept
    • 5.4.2 Teriparatide
    • 5.4.3 Anticoagulants
  • 5.5 Other Drug Classes

6 Global Biosimilars Market, By Manufacturing Type

  • 6.1 Introduction
  • 6.2 In-house Manufacturing
  • 6.3 Contract Manufacturing

7 Global Biosimilars Market, By Technology

  • 7.1 Introduction
  • 7.2 Mass Spectroscopy
  • 7.3 Chromatography
  • 7.4 Monoclonal Antibody Technology
  • 7.5 Recombinant DNA Technology
  • 7.6 Nuclear Magnetic Resonance (NMR) Technology
  • 7.7 Electrophoresis
  • 7.8 Bioassay

8 Global Biosimilars Market, By Application

  • 8.1 Introduction
  • 8.2 Hematology
    • 8.2.1 Neutropenia
    • 8.2.2 Anemia
  • 8.3 Oncology
    • 8.3.1 Lung Cancer
    • 8.3.2 Brain Cancer
    • 8.3.3 Breast Cancer
    • 8.3.4 Cervical Cancer
    • 8.3.5 Colorectal Cancer
    • 8.3.6 Leukemia
      • 8.3.6.1 Non-Hodgkin Lymphoma (NHL)
      • 8.3.6.2 Chronic Lymphocytic Leukemia (CLL)
  • 8.4 Chronic Diseases
  • 8.5 Autoimmune Disease
    • 8.5.1 Arthritis
      • 8.5.1.1 Rheumatoid Arthritis
      • 8.5.1.2 Psoriatic Arthritis
      • 8.5.1.3 Juvenile Arthritis
      • 8.5.1.4 Ankylosing Spondylitis
    • 8.5.2 Inflammatory Bowel Disease (IBD)
      • 8.5.2.1 Ulcerative Colitis
      • 8.5.2.2 Crohn's Disease
    • 8.5.3 Psoriasis
  • 8.6 Blood Disorders
  • 8.7 Growth Hormone Deficiency
  • 8.8 Diabetes
  • 8.9 Other Applications

9 Global Biosimilars Market, By End User

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 Online Pharmacies
  • 9.5 Other End Users

10 Global Biosimilars Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Coherus Biosciences Inc.
  • 12.2 Boehringer Ingelheim International GMBH
  • 12.3 Eli Lilly and Company
  • 12.4 Fresenius Kabi Ag
  • 12.5 Samsung Bioepis Co. Ltd
  • 12.6 Amgen Inc.
  • 12.7 LG Life Sciences (LG Chem)
  • 12.8 Celltrion Healthcare
  • 12.9 Biocad
  • 12.10 Dr. Reddy's Laboratories LTD.
  • 12.11 Viatris Inc.
  • 12.12 Intas Pharmaceutical Ltd
  • 12.13 Biocon Limited
  • 12.14 Teva Pharmaceutical Industries Ltd
  • 12.15 Pfizer Inc.
  • 12.16 Stada Arzneimittel AG
  • 12.17 Novartis AG

List of Tables

  • Table 1 Global Biosimilars Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Biosimilars Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 3 Global Biosimilars Market Outlook, By Recombinant Non-Glycosylated Proteins (2021-2030) ($MN)
  • Table 4 Global Biosimilars Market Outlook, By Recombinant Human Growth Hormone (2021-2030) ($MN)
  • Table 5 Global Biosimilars Market Outlook, By Granulocyte Colony-Stimulating Factor (2021-2030) ($MN)
  • Table 6 Global Biosimilars Market Outlook, By Insulin (2021-2030) ($MN)
  • Table 7 Global Biosimilars Market Outlook, By Interferons (2021-2030) ($MN)
  • Table 8 Global Biosimilars Market Outlook, By Recombinant Glycosylated Proteins (2021-2030) ($MN)
  • Table 9 Global Biosimilars Market Outlook, By Erythropoietin (2021-2030) ($MN)
  • Table 10 Global Biosimilars Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 11 Global Biosimilars Market Outlook, By Follitropin (2021-2030) ($MN)
  • Table 12 Global Biosimilars Market Outlook, By Recombinant Peptides (2021-2030) ($MN)
  • Table 13 Global Biosimilars Market Outlook, By Etanercept (2021-2030) ($MN)
  • Table 14 Global Biosimilars Market Outlook, By Teriparatide (2021-2030) ($MN)
  • Table 15 Global Biosimilars Market Outlook, By Anticoagulants (2021-2030) ($MN)
  • Table 16 Global Biosimilars Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 17 Global Biosimilars Market Outlook, By Manufacturing Type (2021-2030) ($MN)
  • Table 18 Global Biosimilars Market Outlook, By In-house Manufacturing (2021-2030) ($MN)
  • Table 19 Global Biosimilars Market Outlook, By Contract Manufacturing (2021-2030) ($MN)
  • Table 20 Global Biosimilars Market Outlook, By Technology (2021-2030) ($MN)
  • Table 21 Global Biosimilars Market Outlook, By Mass Spectroscopy (2021-2030) ($MN)
  • Table 22 Global Biosimilars Market Outlook, By Chromatography (2021-2030) ($MN)
  • Table 23 Global Biosimilars Market Outlook, By Monoclonal Antibody Technology (2021-2030) ($MN)
  • Table 24 Global Biosimilars Market Outlook, By Recombinant DNA Technology (2021-2030) ($MN)
  • Table 25 Global Biosimilars Market Outlook, By Nuclear Magnetic Resonance (NMR) Technology (2021-2030) ($MN)
  • Table 26 Global Biosimilars Market Outlook, By Electrophoresis (2021-2030) ($MN)
  • Table 27 Global Biosimilars Market Outlook, By Bioassay (2021-2030) ($MN)
  • Table 28 Global Biosimilars Market Outlook, By Application (2021-2030) ($MN)
  • Table 29 Global Biosimilars Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 30 Global Biosimilars Market Outlook, By Neutropenia (2021-2030) ($MN)
  • Table 31 Global Biosimilars Market Outlook, By Anemia (2021-2030) ($MN)
  • Table 32 Global Biosimilars Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 33 Global Biosimilars Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 34 Global Biosimilars Market Outlook, By Brain Cancer (2021-2030) ($MN)
  • Table 35 Global Biosimilars Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 36 Global Biosimilars Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 37 Global Biosimilars Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 38 Global Biosimilars Market Outlook, By Leukemia (2021-2030) ($MN)
  • Table 39 Global Biosimilars Market Outlook, By Chronic Diseases (2021-2030) ($MN)
  • Table 40 Global Biosimilars Market Outlook, By Autoimmune Disease (2021-2030) ($MN)
  • Table 41 Global Biosimilars Market Outlook, By Arthritis (2021-2030) ($MN)
  • Table 42 Global Biosimilars Market Outlook, By Inflammatory Bowel Disease (IBD) (2021-2030) ($MN)
  • Table 43 Global Biosimilars Market Outlook, By Psoriasis (2021-2030) ($MN)
  • Table 44 Global Biosimilars Market Outlook, By Blood Disorders (2021-2030) ($MN)
  • Table 45 Global Biosimilars Market Outlook, By Growth Hormone Deficiency (2021-2030) ($MN)
  • Table 46 Global Biosimilars Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 47 Global Biosimilars Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 48 Global Biosimilars Market Outlook, By End User (2021-2030) ($MN)
  • Table 49 Global Biosimilars Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 50 Global Biosimilars Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 51 Global Biosimilars Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 52 Global Biosimilars Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.